"Etoposide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
| Descriptor ID |
D005047
|
| MeSH Number(s) |
D02.455.426.559.847.638.960.675.250 D04.615.638.960.675.250 D09.408.348.275
|
| Concept/Terms |
Etoposide- Etoposide
- Demethyl Epipodophyllotoxin Ethylidine Glucoside
- Eposide
Toposar- Toposar
- Etoposide Teva
- Teva, Etoposide
|
Below are MeSH descriptors whose meaning is more general than "Etoposide".
Below are MeSH descriptors whose meaning is more specific than "Etoposide".
This graph shows the total number of publications written about "Etoposide" by people in this website by year, and whether "Etoposide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 0 | 2 | 2 |
| 1998 | 1 | 1 | 2 |
| 1999 | 1 | 3 | 4 |
| 2000 | 1 | 2 | 3 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 1 | 2 | 3 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 2 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 3 | 3 |
| 2012 | 0 | 2 | 2 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Etoposide" by people in Profiles.
-
Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar; 30(3):2755-2766.
-
Clinical Prognostic Factors and Outcome in Pediatric Osteosarcoma: Effect of Delay in Local Control and Degree of Necrosis in a Multidisciplinary Setting in Lebanon. J Glob Oncol. 2019 04; 5:1-8.
-
A single-institution retrospective cohort study of first-line R-EPOCH chemoimmunotherapy for Richter syndrome demonstrating complex chronic lymphocytic leukaemia karyotype as an adverse prognostic factor. Br J Haematol. 2018 01; 180(2):259-266.
-
Cytomegalovirus-Induced Hemophagocytic Lymphohistiocytosis in an Extreme Preterm Infant: Recognition and Therapy Leading to Recovery. Adv Neonatal Care. 2017 Apr; 17(2):91-95.
-
Chemical Reactivity Window Determines Prodrug Efficiency toward Glutathione Transferase Overexpressing Cancer Cells. Mol Pharm. 2016 06 06; 13(6):2010-25.
-
Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. Asia Pac J Ophthalmol (Phila). 2016 Mar-Apr; 5(2):97-103.
-
SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Mol Cell. 2015 Sep 17; 59(6):917-30.
-
Foveal microanatomy documented by SD-OCT following treatment of advanced retinoblastoma. J AAPOS. 2015 Aug; 19(4):368-72.
-
A Phase I Trial of DFMO Targeting Polyamine Addiction in Patients with Relapsed/Refractory Neuroblastoma. PLoS One. 2015; 10(5):e0127246.
-
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial. Leuk Lymphoma. 2015; 56(9):2569-78.